{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:47:11Z","timestamp":1779295631508,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T00:00:00Z","timestamp":1311638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T00:00:00Z","timestamp":1311638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00280-011-1711-z","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T15:40:14Z","timestamp":1311608414000},"page":"387-395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study"],"prefix":"10.1007","volume":"69","author":[{"given":"Xiao-Jian","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang-Sheng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Ning","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Qiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Fu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Nan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,26]]},"reference":[{"key":"1711_CR1","first-page":"119","volume":"19","author":"NL Harris","year":"2008","unstructured":"Harris NL, Swerdlow S, Campo E, Jaffe ES, Stein H, Pileri S, Thiele J, Vardiman J (2008) The World Health Organization (WHO) classification of lymphoid neoplasms: what\u2019s new? Ann Oncol 19:119","journal-title":"Ann Oncol"},{"issue":"25","key":"1711_CR2","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124\u20134130","journal-title":"J Clin Oncol"},{"issue":"10","key":"1711_CR3","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/annonc\/mdh409","volume":"15","author":"JO Armitage","year":"2004","unstructured":"Armitage JO, Vose JM, Weisenburger DD (2004) Towards understanding the peripheral T-cell lymphomas. Ann Oncol 15(10):1447\u20131449","journal-title":"Ann Oncol"},{"issue":"10","key":"1711_CR4","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM (2004) Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15(10):1467\u20131475","journal-title":"Ann Oncol"},{"issue":"1","key":"1711_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","volume":"79","author":"J Rodriguez","year":"2007","unstructured":"Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J, Bendandi M, Albo C, Caballero MD (2007) Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 79(1):32\u201338","journal-title":"Eur J Haematol"},{"issue":"9","key":"1711_CR6","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","volume":"20","author":"P Corradini","year":"2006","unstructured":"Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20(9):1533\u20131538","journal-title":"Leukemia"},{"issue":"5","key":"1711_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/CCO.0b013e32833d58d9","volume":"22","author":"GG Laport","year":"2010","unstructured":"Laport GG (2010) Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy. Curr Opin Oncol 22(5):409\u2013413","journal-title":"Curr Opin Oncol"},{"key":"1711_CR8","first-page":"443","volume":"40","author":"S Feyler","year":"2007","unstructured":"Feyler S, Prince H, Pearce R (2007) The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study Bone Marrow Transplant 40:443\u2013450","journal-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study Bone Marrow Transplant"},{"issue":"11","key":"1711_CR9","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P, Dodero A, Zallio F (2004) Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22(11):2172\u20132176","journal-title":"J Clin Oncol"},{"issue":"5\u20136","key":"1711_CR10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/10428199909058489","volume":"34","author":"R Hast","year":"1999","unstructured":"Hast R, Jacobsson B, Petrescu A, Hjalmar V (1999) Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia. Leuk Lymphoma 34(5\u20136):597\u2013601","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1711_CR11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1532\/IJH97.05188","volume":"83","author":"M Yamaguchi","year":"2006","unstructured":"Yamaguchi M, Kotani T, Nakamura Y, Ueda M (2006) Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide. Int J Hematol 83(5):450\u2013453","journal-title":"Int J Hematol"},{"issue":"7","key":"1711_CR12","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1200\/JCO.2004.05.012","volume":"22","author":"JF Rossi","year":"2004","unstructured":"Rossi JF, van Hoof A, de Boeck K, Johnson SA, Bron D, Foussard C, Lister TA, Berthou C, Kramer MH, Littlewood TJ, Marcus RE, Deconinck E, Montillo M, Guibon O, Tollerfield SM (2004) Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 22(7):1260\u20131267","journal-title":"J Clin Oncol"},{"issue":"1","key":"1711_CR13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1200\/JCO.2005.03.9313","volume":"24","author":"K Tobinai","year":"2006","unstructured":"Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K, Minami H, Utsunomiya A, Taniwaki M, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Seriu T, Hotta T (2006) Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 24(1):174\u2013180","journal-title":"J Clin Oncol"},{"issue":"10","key":"1711_CR14","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.bcp.2008.02.006","volume":"75","author":"D Damaraju","year":"2008","unstructured":"Damaraju D, Damaraju VL, Brun M, Mowles D, Kuzma M, Berendt RC, Sawyer MB, Cass CE (2008) Cytotoxic activities of nucleoside and nucleobase analog drugs in malignant mesothelioma: characterization of a novel nucleobase transport activity. Biochem Pharmacol 75(10):1901\u20131911","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1711_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1\u201310","journal-title":"Control Clin Trials"},{"issue":"12","key":"1711_CR16","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK\u00a0+\u00a0ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111(12):5496\u20135504","journal-title":"Blood"},{"issue":"1","key":"1711_CR17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","volume":"1","author":"B Coiffier","year":"1990","unstructured":"Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, Diebold J (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d\u2019Etude des Lymphomes Agressives). Ann Oncol 1(1):45\u201350","journal-title":"Ann Oncol"},{"issue":"3","key":"1711_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10198-002-0112-y","volume":"3","author":"M Herold","year":"2002","unstructured":"Herold M, Hieke K (2002) Costs of toxicity during chemotherapy with CHOP, COP\/CVP, and fludarabine. Eur J Health Econ 3(3):166\u2013172","journal-title":"Eur J Health Econ"},{"issue":"2","key":"1711_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000305255","volume":"56","author":"U Disel","year":"2010","unstructured":"Disel U, Paydas S, Yavuz S, Karakoc E (2010) Severe pulmonary toxicity associated with fludarabine and possible contribution of rituximab. Chemotherapy 56(2):89\u201393","journal-title":"Chemotherapy"},{"issue":"3","key":"1711_CR21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1378\/chest.122.3.785","volume":"122","author":"DL Helman Jr","year":"2002","unstructured":"Helman DL Jr, Byrd JC, Ales NC, Shorr AF (2002) Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest 122(3):785\u2013790","journal-title":"Chest"},{"issue":"5","key":"1711_CR22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.hoc.2008.07.010","volume":"22","author":"JM Vose","year":"2008","unstructured":"Vose JM (2008) Peripheral T-cell non-Hodgkin\u2019s lymphoma. Hematol Oncol Clin North Am 22(5):997\u20131005, x","journal-title":"Hematol Oncol Clin North Am"},{"key":"1711_CR23","doi-asserted-by":"publisher","unstructured":"Savage K, Ferreri AJ, Zinzani PL, Pileri SA (2010) Peripheral T-cell lymphoma\u2014not otherwise specified. Crit Rev Oncol Hematol. doi:10.1016\/j.critrevonc.2010.07.007","DOI":"10.1016\/j.critrevonc.2010.07.007"},{"issue":"10","key":"1711_CR24","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escalon","year":"2005","unstructured":"Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, Dang NH (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 103(10):2091\u20132098","journal-title":"Cancer"},{"issue":"4","key":"1711_CR25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/sj.bjc.6602031","volume":"91","author":"L Yung","year":"2004","unstructured":"Yung L, Cunningham D, Hancock B, Smith P, Maclennan K, Linch D, McMillan A (2004) Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI). Br J Cancer 91(4):695\u2013698","journal-title":"Br J Cancer"},{"issue":"Suppl 1","key":"1711_CR26","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1053\/j.seminhematol.2010.01.014","volume":"47","author":"OA O\u2019Connor","year":"2010","unstructured":"O\u2019Connor OA (2010) Novel agents in development for peripheral T-cell lymphoma. Semin Hematol 47(Suppl 1):S11\u2013S14","journal-title":"Semin Hematol"},{"issue":"2","key":"1711_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3324\/haematol.10737","volume":"92","author":"HT Arkenau","year":"2007","unstructured":"Arkenau HT, Chong G, Cunningham D, Watkins D, Sirohi B, Chau I, Wotherspoon A, Norman A, Horwich A, Matutes E (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92(2):271\u2013272","journal-title":"Haematologica"},{"issue":"2","key":"1711_CR28","first-page":"148","volume":"88","author":"D de Totero","year":"2003","unstructured":"de Totero D, Tazzari PL, Capaia M, Montera MP, Clavio M, Balleari E, Foa R, Gobbi M (2003) CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation. Haematologica 88(2):148\u2013158","journal-title":"Haematologica"},{"issue":"24","key":"1711_CR29","first-page":"1459","volume":"143","author":"B Telek","year":"2002","unstructured":"Telek B, Rejto L, Kiss A, Batar P, Remenyi G, Rak K, Udvardy M (2002) Experience with fludarabine treatment and review of the literature. Orv Hetil 143(24):1459\u20131465","journal-title":"Orv Hetil"},{"issue":"11 Suppl","key":"1711_CR30","first-page":"1443","volume":"23","author":"HQ Huang","year":"2004","unstructured":"Huang HQ, Peng YL, Lin XB, Sun XF, Lin TY, Xia ZJ, Li YH, Cai QQ, He YJ, Jiang WQ, Guan ZZ (2004) Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen. Ai Zheng 23(11 Suppl):1443\u20131447","journal-title":"Ai Zheng"},{"issue":"5","key":"1711_CR31","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/annonc\/mdn022","volume":"19","author":"S Mercadal","year":"2008","unstructured":"Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, Camos M, Colomo L, Espinosa I, Martinez S, Ribera JM, Martino R, Gutierrez-Garcia G, Montserrat E, Lopez-Guillermo A (2008) Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19(5):958\u2013963","journal-title":"Ann Oncol"},{"issue":"12","key":"1711_CR32","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1023\/A:1008409601731","volume":"9","author":"PL Zinzani","year":"1998","unstructured":"Zinzani PL, Magagnoli M, Bendandi M, Orcioni GF, Gherlinzoni F, Albertini P, Pileri SA, Tura S (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9(12):1351\u20131353","journal-title":"Ann Oncol"},{"issue":"7","key":"1711_CR33","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, Pinto A, Iannitto E, Zoli V, Torchio P, Pileri S, Tarella C (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110(7):2316\u20132323","journal-title":"Blood"},{"issue":"7","key":"1711_CR34","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/1097-0142(19871001)60:7<1537::AID-CNCR2820600721>3.0.CO;2-S","volume":"60","author":"E Lawlor","year":"1987","unstructured":"Lawlor E, O\u2019Briain DS, Finn T, Ward R, Rogers FM, O\u2019Brien AA, Daly PA (1987) The simultaneous presentation of peripheral T-cell lymphoma and hairy cell leukemia. Cancer 60(7):1537\u20131544","journal-title":"Cancer"},{"issue":"8","key":"1711_CR35","first-page":"943","volume":"23","author":"YL Peng","year":"2004","unstructured":"Peng YL, Huang HQ, Lin XB, Xia ZJ, Li YH, Wang W, He YJ, Pan ZH, Jiang WQ, Guan ZZ (2004) Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen. Ai Zheng 23(8):943\u2013946","journal-title":"Ai Zheng"},{"issue":"5","key":"1711_CR36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1600-0609.2010.01411.x","volume":"84","author":"Y Takamatsu","year":"2010","unstructured":"Takamatsu Y, Suzumiya J, Utsunomiya A, Maeda K, Matsuoka H, Suzushima H, Tsukada J, Shibata K, Tamura K (2010) THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia\/lymphoma: a multicenter phase II study. Eur J Haematol 84(5):391\u2013397","journal-title":"Eur J Haematol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1711-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-011-1711-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1711-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1711-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:39:46Z","timestamp":1659058786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-011-1711-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,26]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["1711"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1711-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,26]]},"assertion":[{"value":"2 May 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}